The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

References

• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature0598417625570
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–1203. doi:10.1016/j.cell.2007.11.02518083107
   PubMed Web of Science ®Google Scholar
• Miyanaga A, Shimizu K, Noro R, et al. Activity of EGFRtyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-smallcell lung cancer harbored coexisting EGFR mutation. BMC Cancer. 2013;13:262–267. doi:10.1186/1471-2407-13-26223714228
   PubMed Web of Science ®Google Scholar
• Hou H, Zhu H, Yan W, et al. Comprehensive molecular characterization of young Chinese patients with lung adenocarcinoma identified a distinctive genetic profile. Oncologist. 2018;23(9):1–8. doi:10.1634/theoncologist.2017-062929158364
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703. doi:10.1056/NEJMoa101120520979469
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa121488623724913
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177. doi:10.1056/NEJMoa141049025470694
   PubMed Web of Science ®Google Scholar
• Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M. Lung toxicity in non-small cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clin Lung Cancer. 2017;19(2):e151–e161. doi:10.1016/j.cllc.2017.10.00829174221
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Okamoto I, Otsubo K, et al. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib. Invest New Drugs. 2015;33(5):1148–1150. doi:10.1007/s10637-015-0284-926334220
   PubMed Web of Science ®Google Scholar
• Ikeda S, Yoshioka H, Arita M, et al. Interstitial lung disease induced by alectinib (CH5424802/RO5424802). Jpn J Clin Oncol. 2015;45(2):221–224. doi:10.1093/jjco/hyu18325398579
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi:10.1007/s10654-010-9491-z20652370
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d592822008217
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [homepage on the Internet]. NCT01945021. Study results; 2019 [updated February 15, 2018; cited June 16, 2018]. Available from: https://www.clinicaltrials.gov/ct2/results?cond=&term=NCT01945021. Accessed April 17, 2019.
   Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi:10.1056/NEJMoa170479528586279
   PubMed Web of Science ®Google Scholar
• Lu S, Mok T, Lu Y, et al. Phase 3 study of first-line crizotinib vs pemetrexed-cisplatin/carboplatin in East Asian patients with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(suppl). doi:10.1200/JCO.2016.34.15_suppl.9058
   Google Scholar
• Blackhall F, Canidge DR, Shaw AT, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non small-cell lung cancer. ESMO Open. 2017;2(3):e000219. doi:10.1136/esmoopen-2017-00021929209525
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer. Lancet Oncol. 2016;17(2):234–242. doi:10.1016/S1470-2045(15)00488-X26708155
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, Petris LD, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661–668. doi:10.1200/JCO.2015.63.944326598747
   PubMed Web of Science ®Google Scholar
• Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013;14(7):590–598. doi:10.1016/S1470-2045(13)70142-623639470
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlle, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886. doi:10.1016/S1470-2045(17)30072-428602779
   PubMed Web of Science ®Google Scholar
• Crinò L, Ahn MJ, Marinis FD, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;20(34):2866–2873. doi:10.1200/JCO.2015.65.5936
   Google Scholar
• Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet Oncol. 2017;389(10072):917–929. doi:10.1016/S0140-6736(17)30123-X
   Google Scholar
• Kim DW, Mehra R, Tan DSW, et al. Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–463. doi:10.1016/S1470-2045(15)00614-226973324
   PubMed Web of Science ®Google Scholar
• Nishio M, Murakami H, Horiike A, et al. Phase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors. J Clin Oncol. 2015;10(7):1058–1066.
   Google Scholar
• Camidge DR, Kim DW, Tiseo M, et al. Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J Clin Oncol. 2018;36(26):2693–2701. doi:10.1200/JCO.2017.77.584129768119
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(12):1683–1696. doi:10.1016/S1470-2045(16)30392-827836716
   PubMed Web of Science ®Google Scholar
• Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235. doi:10.2188/jea.15.23516276033
   PubMed Web of Science ®Google Scholar
• Costa RB, Costa RLB, Talamantes SM, et al. Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. Oncotarget. 2018;9(31):22137–22146. doi:10.18632/oncotarget.2515429774128
   PubMedGoogle Scholar
• Zhu Q, Hu H, Jiang F, et al. Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC. Oncotarget. 2017;8(43):75372–75380.29088872
   PubMedGoogle Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): resultsfrom the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–1128. doi:10.1016/S1470-2045(13)70510-225153538
   PubMed Web of Science ®Google Scholar